Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques.

Published

Journal Article

Sirolimus is a potent antiproliferative agent used clinically to prevent renal allograft rejection. However, little is known about the effects of maintenance immunosuppressive agents on the immune response to potentially protective vaccines. Here we show that sirolimus paradoxically increases the magnitude and quality of the CD8+ T-cell response to vaccinia vaccination in nonhuman primates, fostering more robust recall responses compared to untreated and tacrolimus-treated controls. Enhancement of both the central and effector memory compartments of the vaccinia-specific CD8+ T-cell response was observed. These data elucidate new mechanistic characteristics of sirolimus and suggest immune applications extending beyond its role as an immunosuppressant.

Full Text

Duke Authors

Cited Authors

  • Turner, AP; Shaffer, VO; Araki, K; Martens, C; Turner, PL; Gangappa, S; Ford, ML; Ahmed, R; Kirk, AD; Larsen, CP

Published Date

  • March 2011

Published In

Volume / Issue

  • 11 / 3

Start / End Page

  • 613 - 618

PubMed ID

  • 21342450

Pubmed Central ID

  • 21342450

Electronic International Standard Serial Number (EISSN)

  • 1600-6143

Digital Object Identifier (DOI)

  • 10.1111/j.1600-6143.2010.03407.x

Language

  • eng

Conference Location

  • United States